Detection of residual disease in acute lymphoblastic leukemia of childhood

Leukemia and Lymphoma

Volumn 33, Issue 1-2, 1999, Pages 47-52

  Estrov, Zeev ^a   Freedman, Melvin H ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute lymphoblastic leukemia; ALL detection of residual disease; Childhood leukemia

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CHILD; CHILDHOOD LEUKEMIA; DIAGNOSTIC ACCURACY; HUMAN; INFANT; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW;

EID: 0033009555     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909093724     Document Type: Review

References (35)

1. Estrov Z., Grunherger T, Dube ID, Wang Y-P, Freedman MH. Detection of residual acute lymphoblastic cells in cultures of bone marrow obtained during remission. N Engl J Med 42:315-538, 1986.
2. Campana D. Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85:1416-1434, 1995.
3. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia: persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 55:323-448, 1990.
4. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma 20:181-197, 1996.
5. Ito Y, Wasserman R, Galili N, Reichard BA, Shane S, Lang B, Rovera G. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin oncol 11:546-53, 1993.
6. Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 217:75-83, 1993.
7. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukemia. Br J Haematol 83:412-8, 1993.
8. H-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood 81:775-782 1993.
9. Steenbergen EJ, Verhagen OJHM, Van Leeuwen EF, Von dem Borne AEGK. Vander Schoot CE. District ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 82:581-589, 1993.
10. Estrov Z, Ouspenskaia MN, Felix EA, McClain KL, Lee M-S, Harris D, Pinkel DP, Zipf TF. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 8:46-52, 1994.
11. Steward CG, Goulden NJ, Katz, F. Baines D, Martin PG, Langlards K, Potter MN, Chessells JM, and Oakhill A. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor gene rearrangement between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 83:1355-1362, 1994.
12. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336:317-323, 1997.
13. Nizet Y, Martiat P, Vaerman JL, Philippe M, Wildmann C, Staelens JP, Cornu G, Ferrant A, Michaux JL, Sokal G, Follow-up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 79:205-10, 1991.
14. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 9:321-8, 1995.
15. Ito Y, Miyamura K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Leuk Lymphoma 16:57-64, 1994.
16. Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther 1:65-9, 1995.
17. Greaves M. A natural history for pediatric acute leukemia. Blood 82:1043-1051, 1993.
18. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukemia. Lancet 338:1315-8, 1991.
19. Chang K-S, Fan Y-H, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H. Expression of AMLI-ETO fusion transcripts and detection of minimal residual disease in t(8:21)-positive acute myeloid leukemia. Oncogen 8:983-8, 1993.
20. Nucifora G, Larson RA, Rowley JD. Persistence of the 8:21 translation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712-5, 1993.
21. Jurlander J, Caliguiri M, Ruutu T, Baer MR. Strout MP, Oberkircher AR, Hoffman L, Ball ED, Frei-Lahr DA, Christiansem NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML/ETO fusion transcript in patients treated with allogencic bone marrow transplantation for t(8:21) leukemia. Blood 88:2183-91, 1996.
22. Satake N, Maseki N, Kozu T, Sakashita A, Kohayashi H, Sakurai M, Ohki M, Kaneko Y. Disappearance of AMLI-MTG8 (ETO) fusion transcript in acute myeloid leukemia patients with t(8:21) in long-term remission. Br J Haematol 91 :892-8, 1995.
23. Birnie GD, MacKenzie ED, Goyns MH, Pollock A. Seques-tration of Philadelphia chromosome-positive cells in the bone marrow of a chronic myeloid leukemia patient in very prolonged remission. Leukemia 4:452-454, 1990.
24. Musashi M, Abe S, Yamada T, Tanaka J, Gotohda Y, Maeda S, Sato Y, Morioka M, Sakurada K, Minagawa T, Asaka M, Miyazaki T. Spontaneous remission in a patient with chronic myelogenous leukemia. N Engl J Med 336:337-339, 1997.
25. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86:3118-22, 1995.
26. Montagna D, Arico M, Montini E, De Benedetti F, Maccario R. Identification of HLA-unrestricted CD8 +/CD28-cytotoxic T-cell specific for leukemic blasts in children with acute leukemia. Cancer res 55:3835-9, 1995.
27. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ 309:162-6, 1994.
28. Wu N-H, Lu S-G, Zhu P, Peng Y-Y. Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy. Pediatr Hematol Oncol 13:257-63, 1996.
29. Nizet T, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martial P, Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82:1618-25, 1993.
30. Yokota S, Hansen-Hagge TE, Ludwig W-D, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77:331-9, 1991.
31. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 343:196-200, 1994.
32. Snodgrass R, Keller G. Clonal fluctuation within the hematopoietic system of mice reconstituted with retrovirus-infected stem cells. EMBO J 6:3955-60, 1987.
33. Cave H, Guidal P, Rohrlich P, Delfau MH, Broyart A. Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, D'Auriol L, Elion J, Vilmer E, Grandchamp B. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of and T-cell receptor genes. Blood 83:1892-1902, 1 994.
34. Chandry M. childhood acute lymphoblastic leukemia in India: an approach to management in three-tier society. Med Pediat Oncol 25:197-203, 1995.
35. Pinkel D. Lessons from 20 years of curative therapy of childhood acute leukemia. Br J Cancer 65:148-53, 1992.